CMS Unveils Clinical Super Intelligence Roadmap
The Centers for Medicare & Medicaid Services released a roadmap for regulating and paying for AI in healthcare.
Updated on Nov. 16, 2026 in Artificial Intelligence

Live Poll
Would you trust an AI tool to handle part of your routine checkup?
The Centers for Medicare & Medicaid Services (CMS) released a clinical super intelligence roadmap for regulating and paying for artificial intelligence in healthcare. The roadmap uses "super intelligence" as the Trump administration's term for what it formerly called AI.
Why it matters
The roadmap sets out how AI tools may be evaluated, deployed and reimbursed in clinical settings, with CMS holding clinical AI to a "better than today" standard for safety, effectiveness, access and outcomes. It does not mandate AI adoption or create a new agency.
The roadmap cites Microsoft research in which its MAI-DxO tool correctly diagnosed 85.5% of challenging cases, compared with about 20% for practicing physicians. CMS's Health Tech Ecosystem grew from more than 60 company commitments to more than 800, though the extraction does not detail how those commitments are verified.
The players
Centers for Medicare & Medicaid Services (CMS)
The federal agency that administers Medicare and Medicaid and oversees the health care payment programs affected by the roadmap.
Food and Drug Administration (FDA)
The federal regulator that reviews and authorizes medical devices, and which may adopt a competency-based premarket review for certain AI-enabled devices under the roadmap.
The details
The roadmap rests on four pillars: earning public trust, building the data foundation, establishing clear rules of the road, and paying for what works. CMS flagged risks including hallucinations, uneven performance across populations, commercial conflicts of interest, and privacy and cybersecurity vulnerabilities, and said greater autonomy for clinical AI must be earned through evidence, staged deployment and real-world monitoring.
Timeline
December 2025: CMS announced the ACCESS model, which the roadmap builds on.
January 2026: The FDA TEMPO pilot launched alongside ACCESS.
Nov. 13, 2026: CMS released the clinical super intelligence roadmap.
Roadmap
The roadmap builds directly on the ACCESS model CMS announced in December 2025 and proposes extending it to primary care for more chronic conditions. It positions federal AI oversight as a shift from pilot programs toward payment structures for AI tools that meet evidence-based standards.
The roadmap signals that AI tools used in clinical care may increasingly be reimbursed by Medicare if they meet evidence and safety standards. Patients may see AI tools in routine care, including possible delivery of parts of the Medicare Annual Wellness Visit through AI, though the extraction does not state when such changes would take effect.
The takeaway
AI tools in healthcare will likely need to show measurable performance gains over current practice before they win federal payment. Readers should watch for FDA and CMS rulemaking that turns the roadmap's standards into binding requirements.
Further reading
For broader coverage of federal AI policy, see Artificial Intelligence.
Live Poll
Would you trust an AI tool to handle part of your routine checkup?









